Report Code : CVMI29123859 | Published Date : March 26, 2025

Market Overview:

The European clinical trials market is rapidly evolving, driven by regulatory harmonization under the EU Clinical Trials Regulation (CTR), increased investment in decentralized trials, and growth in research on oncology, rare diseases, and precision medicine. Leading research hubs in Germany, France, the UK, and the Netherlands are complemented by a rise in trial activity in Eastern Europe, which is due to cost efficiency and faster patient recruitment.

 

Market Size and Forecast

Year

Market Value (USD Billion)

Notes

2019

11.6

Covers Phase I–IV across pharma, biotech, and medical device segments

2024

16.5

CAGR 7.3% (2019–2024); accelerated by COVID-era trial digitization

2031

25.8

CAGR 6.5% (2024–2031); sustained by rare disease and oncology expansion

 

Market Drivers

  • EU Clinical Trials Regulation (CTR) facilitates single-portal, cross-border applications.
  • Strong academic research infrastructure and public-private partnerships (IMI, ECRIN)
  • Growth in rare disease and pediatric trials supported by EU orphan incentives
  • Adoption of digital recruitment, eConsent, and remote monitoring tools
  • Increasing presence of global CROs and trial sponsors in CEE countries

 

Market Challenges

  • Varying data privacy laws (GDPR) complicating digital trial design
  • Workforce shortages in clinical research nurses and data managers
  • Cost constraints and delays due to multi-country protocol customization

 

Competitive Landscape

Company

Core Strengths

Recent Developments

ICON plc

Oncology trials, DCT platforms

Expanded European HQ in Amsterdam (2024)

IQVIA

Data-driven trials, tech-enabled monitoring

Launched GDPR-compliant eConsent suite (2025)

Labcorp Drug Dev

Early-phase research, biosample logistics

Added EU-wide biomarker lab in Germany (2024)

PPD (Thermo Fisher)

Global reach, regulatory strategy expertise

Partnered with ECRIN for rare disease trials (2025)

 

Regional Insights

  • Western Europe – High trial density and sponsor activity, especially in oncology
  • Central & Eastern Europe – Cost-efficient recruitment and faster start-up timelines
  • Nordics – Pioneering DCTs and biobank-linked studies




Reasons To Buy

Image



Scope

Image

Key Players

  • IQVIA
  • ICON plc
  • Parexel International
  • Labcorp Drug Development (Covance)
  • PPD (part of Thermo Fisher Scientific)
  • Syneos Health
  • Charles River Laboratories
  • Medpace
  • WuXi AppTec
  • PRA Health Sciences
  • Clinipace
  • PSI CRO
  • Covance Inc.
  • AstraZeneca
  • Novo Nordisk

 

Clinical Trials Market Report

 

  1. 1. Clinical Trials Market Research Report
    1. 1.1 Study Objectives
    2. 1.2 Clinical Trials Market - Overview
    3. 1.3 Reason to Read This Report
    4. 1.4 Methodology and Forecast Analysis
  2. 2. Clinical Trials Market Research Report - Preface
    1. 2.1 Clinical Trials Market Research Report – Detailed Scope and Definitions
      1. 2.1.1 By Phase:
      2. 2.1.2 By Study Design
      3. 2.1.3 By Therapeutic Area
      4. 2.1.4 By Region
  3. 3. Clinical Trials Market Dynamics
    1. 3.1. Drivers - Macro-Economic Based, Supply Side, and Demand Side Drivers
    2. 3.2. Restraints – By Phase:, By Study Design, By Therapeutic Area, By Country
    3. 3.3. Opportunities – By Phase:, By Study Design, By Therapeutic Area, By Country
    4. 3.4. Trends – By Phase:, By Study Design, By Therapeutic Area, By Country
    5. 3.5. PEST Analysis
    6. 3.6. Porters Five Rule Analysis
    7. 3.7. Company’s Share Analysis (CSA) by Region or By Country
    8. 3.8. Clinical Trials Market Research Report – DROTs Impact Analysis
    1. 4. Clinical Trials Market Research Report, Historic Data 2019 - 2023 and Forecast Analysis Data 2024 - 2031
    2. 4.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    3. 4.2. Annual Market Trend Assessment – Year-on-Year (YoY) Growth Analysis (%)
    4. 4.3. Incremental Market Value/Volume Opportunity between 2019 - 2023 and 2024 - 2031
    5. 4.4. Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
  1. 5. Clinical Trials Market, By Phase:, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 5.1 Phase I – Safety and dosage testing (small group),
    2. 5.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    3. 5.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    4. 5.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    5. 5.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. 5.2 Phase II – Efficacy and side effects (medium-sized group)
    7. 5.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    8. 5.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    9. 5.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    10. 5.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    11. 5.3 Phase III – Confirmation of effectiveness and monitoring of side effects (large group)
    12. 5.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    13. 5.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    14. 5.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    15. 5.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    16. 5.4 Phase IV – Post-marketing surveillance after drug approval
    17. 5.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    18. 5.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    19. 5.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    20. 5.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. Clinical Trials Market, By Study Design, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 6.1 Interventional Trials – Participants receive specific interventions (e.g., drug, procedure)
    2. 6.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    3. 6.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    4. 6.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    5. 6.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. 6.2 Observational Trials – Outcomes are observed without assigning interventions
    7. 6.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    8. 6.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    9. 6.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    10. 6.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    11. 6.3 Expanded Access Trials – For patients not eligible for clinical trials to access investigational treatments
    12. 6.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    13. 6.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    14. 6.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    15. 6.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    7. Clinical Trials Market, By Therapeutic Area, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 7.1 Oncology (Cancer)
    2. 7.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    3. 7.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    4. 7.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    5. 7.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. 7.2 Cardiovascular Diseases
    7. 7.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    8. 7.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    9. 7.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    10. 7.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    11. 7.3 Infectious Diseases (e.g., COVID-19, HIV)
    12. 7.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    13. 7.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    14. 7.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    15. 7.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    16. 7.4 Neurological Disorders
    17. 7.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    18. 7.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    19. 7.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    20. 7.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    21. 7.5 Autoimmune/Inflammatory Diseases
    22. 7.5.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    23. 7.5.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    24. 7.5.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    25. 7.5.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
  1. 8. Clinical Trials Market Forecast, By Region, 2019 - 2023 and 2024 - 2031 (Market Value, In USD Mn)
    1. 8.1 Europe
      1. 8.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 8.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 8.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 8.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      8.2 Clinical Trials Market - Opportunity Analysis Index, By Phase:, By Study Design, By Therapeutic Area, and Region, 2024 - 2031
  1. 9. Europe Clinical Trials Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 9.1 By Phase: Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.1.1 Phase I – Safety and dosage testing (small group),
      2. 9.1.2 Phase II – Efficacy and side effects (medium-sized group)
      3. 9.1.3 Phase III – Confirmation of effectiveness and monitoring of side effects (large group)
      4. 9.1.4 Phase IV – Post-marketing surveillance after drug approval
      9.2 By Study Design Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.2.1 Interventional Trials – Participants receive specific interventions (e.g., drug, procedure)
      2. 9.2.2 Observational Trials – Outcomes are observed without assigning interventions
      3. 9.2.3 Expanded Access Trials – For patients not eligible for clinical trials to access investigational treatments
      9.3 By Therapeutic Area Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.3.1 Oncology (Cancer)
      2. 9.3.2 Cardiovascular Diseases
      3. 9.3.3 Infectious Diseases (e.g., COVID-19, HIV)
      4. 9.3.4 Neurological Disorders
      5. 9.3.5 Autoimmune/Inflammatory Diseases
      9.4 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.4.1 Germany
      2. 9.4.2 United Kingdom
      3. 9.4.3 France
      4. 9.4.4 Spain
      5. 9.4.5 Italy
      6. 9.4.6 Russia
    2. 9.5 Europe Clinical Trials Market – Opportunity Analysis Index, By Phase:, By Study Design, By Therapeutic Area, and Country, 2024 - 2031
    3. 9.6 Regional Trends Analysis
    4. 9.7 Europe Clinical Trials Market Research Report - Company Profiles
      1. 9.7.1 Company 1 (Germany)
      2. 9.7.2 Company 2 (United Kingdom)
      3. 9.7.3 Company 3 (United Kingdom)
    10. Competition Landscape
    1. 10.1 Strategic Dashboard of Top Market Players
    2. 10.2 Company Profiles (Introduction, Financial Assessments, Portfolio of Offerings, Milestones and Achievements, Strategic Initiative, and SWOT Analysis)
      1. 10.2.1 IQVIA
      2. 10.2.2 ICON plc
      3. 10.2.3 Parexel International
      4. 10.2.4 Labcorp Drug Development
      5. 10.2.5 PPD
      6. 10.2.6 Syneos Health
      7. 10.2.7 Charles River Laboratories
      8. 10.2.8 Medpace
      9. 10.2.9 WuXi AppTec
      10. 10.2.10 PRA Health Sciences
      11. 10.2.11 Clinipace
      12. 10.2.12 PSI CRO
      13. 10.2.13 Covance Inc.
      14. 10.2.14 AstraZeneca
      15. 10.2.15 Novo Nordisk
  1. 11. Data Collection Method and Research Approach
  2. 12. Principal Presumptions and Acronyms